Nanobiotix Initiates US Patient Enrollment of P-III Trial (NANORAY-312) for Head and Neck Cancer
Shots:
- The first US patient has been enrolled in the NANORAY-312 registrational trial evaluating NBTXR3 ± cetuximab vs RT ± cetuximab in a ratio (1:1) in elderly patients with LA-HNSCC. EU & Asia recruitment initiated in Jan 2022 & Aug 2022
- The trial is being conducted in collaboration with LianBio (in Asia) with 500 patients expected to be recruited across 80 sites globally majorly in the US, EU, and Asia. The P-III futility analysis is expected in H2’23 with an anticipated interim result in H2’24
- The P-I dose escalation and dose expansion study showed favorable safety data and early signs of efficacy and NBTR3 received FTD from US FDA
Ref: Globenewswire | Image: Nanobiotix
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
